AMN Healthcare price target lowered to $47 from $50 at Truist

Truist lowered the firm’s price target on AMN Healthcare (AMN) to $47 from $50 and keeps a Buy rating on the shares. The company reported mixed Q3 results and issued downside Q4 guidance as EBITDA margins fell 500bps, the analyst tells investors in a research note. Truist adds however that demographic shifts, increasingly complex regulatory requirements, and AMN’s high quality interpreters should enable market share gain opportunities for the language services division.